Apellis Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Apellis Pharmaceuticals, Inc.

Mar-31	Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology APLS +135.40% GlobeNewswire
Mar-02	Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors APLS GlobeNewswire
Feb-24	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results APLS GlobeNewswire
Feb-23	Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference APLS GlobeNewswire
Feb-19	Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting APLS GlobeNewswire
Feb-10	Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results APLS GlobeNewswire
Jan-12	Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference APLS -15.02% GlobeNewswire
Jan-05	Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference APLS GlobeNewswire
Dec-03	The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN APLS GlobeNewswire
Nov-25	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences APLS GlobeNewswire
Nov-12	Apellis Announces 5-Year GALE Data Showing SYFOVRE (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years APLS GlobeNewswire
Nov-05	Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference APLS GlobeNewswire
Oct-30	Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results APLS -31.01% GlobeNewswire
Oct-20	New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week APLS +10.40% GlobeNewswire
Oct-16	Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results APLS GlobeNewswire
Aug-27	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences APLS GlobeNewswire
Jul-31	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results APLS +17.58% GlobeNewswire
Jul-28	FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older APLS GlobeNewswire
Jul-24	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results APLS GlobeNewswire
Jul-15	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting APLS GlobeNewswire
Jul-01	Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan) APLS GlobeNewswire
Jun-04	Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference APLS GlobeNewswire
May-07	Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results APLS -5.91% GlobeNewswire
May-06	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences APLS GlobeNewswire

Apellis Pharmaceuticals, Inc.

Recent Articles by Apellis Pharmaceuticals, Inc.

Upgrade your Finviz experience